AbbVie backs Kestrel’s pan-KRAS program with option-to-buy deal

Kestrel Therapeutics said it has dosed the first patient in its Phase 1 FALCON trial of KST-6051, an oral pan-KRAS inhibitor for KRAS-driven solid tumors, and disclosed a new AbbVie deal tied to the program. Under the agreement, AbbVie will fund development of KST-6051 and receive an exclusive option to acquire Kestrel if certain development and regulatory milestones are met. Including the upfront payment, option exercise payments, and downstream milestones, the transaction could be worth up to $1.45 billion. KST-6051 cleared the FDA IND process in March 2026, and Kestrel has said initial clinical readouts are anticipated in late 2026. (globenewswire.com)

Why it matters: For veterinary professionals, this is primarily a signal about where oncology drug development money is moving, not a practice-changing animal health update. AbbVie is making a sizable early-stage bet on pan-KRAS biology, a target area with broad relevance because KRAS mutations are common across human cancers. The structure also stands out: rather than buying the company outright now, AbbVie is using a funded option-to-acquire model that lets it back the asset through early clinical proof-of-concept before deciding on a full takeout. That kind of staged dealmaking has become an increasingly important feature of biotech financing and oncology pipeline strategy. (globenewswire.com)

What to watch: Watch for initial Phase 1 safety and early efficacy signals from KST-6051 in late 2026, since those data are likely to shape whether AbbVie exercises its acquisition option. (kestreltherapeutics.com)